查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球激素替代疗法 (HRT) 市场
市场调查报告书
商品编码
1140670

2022-2029 年全球激素替代疗法 (HRT) 市场

Global Hormone Replacement Therapy (HRT) Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

到 2021 年，激素替代疗法 (HRT) 市场价值将达到 145.535 亿美元。预计在预测期内（2022-2029 年）将以 5.1% 的复合年增长率增长。

激素替代疗法 (HRT) 是一种替代或替代体内不足以达到正常生理所需水平的激素的技术。激素替代疗法有助于平衡绝经期间或接近绝经期的雌激素和孕激素水平。在更年期、激素治疗或更年期激素治疗期间，激素替代疗法可以帮助缓解潮热、出汗和其他更年期症状。 HR 疗法也被证明可以预防绝经后妇女的骨质流失和减少骨折。全身激素疗法以片剂、乳膏、喷雾剂、皮肤贴剂和凝胶的形式出现，是缓解更年期潮热和盗汗的最有效疗法之一。

市场动态

激素替代疗法市场的增长受到主要因素的推动，例如女性更年期意识的提高、新给药系统的药物开发增加以及与人口老龄化相关的激素失衡增加。

随着老年人口的增加，荷尔蒙失调的加剧正在推动 HRT 市场的增长

随着老年人口的增加，荷尔蒙失调症是推动 HRT 市场增长的主要因素之一。由于一些荷尔蒙的变化，女性身体主要受到自然衰老过程的影响，导致异常和疾病。常见问题包括疲劳、体重增加、记忆力减退、性慾下降、外观老化和肌肉损失。

由于与年龄相关的荷尔蒙变化，最常见的情况与更年期有关。全球女性绝经的平均年龄约为 50 岁。在女性中，雌激素和孕激素水平在 50 岁后显着下降。这种雌激素和孕激素分泌的减少由垂体补偿，垂体增加促卵泡激素 (FSH) 的分泌。这以潮热的形式表现出来，这是更年期的症状。

激素替代疗法的发展增加

激素替代疗法市场在过去几年经历了显着发展，预计在预测期内将出现显着增长。随着荷尔蒙失调问题的频率增加以及年龄和新生儿人口的增加，预计这些疾病将继续发展。常规观察细节的存在、药物输送框架领域的技术进步以及患者意识的提高推动了对激素替代疗法的日益浓厚的兴趣。更年期女性是影响市场的最大部分，预计 45-59 岁女性人口的增加和更年期窗口的扩大将推动发展。

2020 年 1 月，加利福尼亚州推出了一项新的更年期健康服务，首次为女性提供远程医疗咨询和更年期激素替代疗法的远程医疗处方。这个名为 CurieMD 的远程医疗平台为消费者提供与董事会认证的中年健康从业者的视频咨询（免费开始，后续预约 39 美元）。 FDA 批准的生物同质激素疗法可作为口服片剂、阴道乳膏、口服避孕药和季度付款计划使用。

与 HRT 相关的副作用和风险可能会阻碍市场增长

激素替代疗法有一些副作用，包括消化不良、抑郁、体液潴留和头痛。预计这些副作用会阻碍这种疗法的采用。

激素替代疗法可能会给患有不受控制的高血压、血栓形成、血液甘油三酯水平、中风、心脏病、乳腺癌和胆囊疾病的人带来多种风险。

此外，根据英国 NICE 的调查结果，激素替代疗法与黄体酮和雌激素药物联合使用时会增加患乳腺癌的风险。长期使用 HRT 药物也可能增加血栓的风险。一项研究发现，每 1,000 名服用 HRT 片剂 7.5 年的女性中，只有不到 2 名出现血栓。

流行病学

甲状腺功能减退。

全国健康和营养检查调查 (NHANES 1999-2002) 报告称，在代表美国的 4392 名甲状腺功能减退症患者中，有 3.7% 的人患有甲状腺功能减退症（定义为 TSH 水平 >4.5 mIU/L）。甲状腺功能减退症在出生时体型较小且儿童时期肥胖程度较低的女性中更为常见。

导致甲状腺功能减退的碘缺乏症在最不发达国家更为常见。定期用碘补充盐、麵粉和其他主食已降低碘缺乏率。

世界卫生组织 (WHO) 在 1994 年 1 月至 2006 年 12 月期间针对 130 个国家/地区的数据发现，30.6% 的人口碘营养不足。 WHO 建议一般人群的尿碘浓度范围为 100-199 hoshi g/L，孕妇的尿碘浓度范围为 150-249 hoshi g/L。

甲状腺功能减退、甲状腺肿和甲状腺结节的频率随着年龄的增长而增加。甲状腺功能减退症在老年人中最常见，2-20% 的老年人群患有某种形式的甲状腺功能减退症。在 Framingham 研究中，5.9% 的 60 岁及以上女性和 2.4% 的男性患有甲状腺功能减退症（TSH >10 mIU/L）。在 NHANES 1999-2002 中，80 岁以上的人患甲状腺功能减退症的可能性是 12-49 岁的人的五倍。

NHANES 1999-2002 报告说，白种人 (5.1%) 和墨西哥裔美国人的甲状腺功能减退症患病率高于非洲裔美国人 (1.7%)。非裔美国人的 TSH 水平中值也往往较低。

市场细分

全球激素替代疗法 (HRT) 市场根据产品、疾病类型、给药途径和分销渠道进行细分。

根据疾病，预计在预测期内更年期将以高复合年增长率增长

更年期是月经週期结束的阶段。 12个月未来月经时诊断。更年期发生在 40 或 50 岁。更年期是一个自然的生物过程。激素替代疗法，无论是在更年期还是更晚开始，都可以提高老年女性的生活质量并延长寿命。这种疗法有助于老年妇女维持雌激素水平。

随着全球老龄化人口的增加，绝经期的增长预计会增加。联合国估计，到 2020 年，全球将有 9.8 亿女性年龄在 50 岁以上。可以进一步估计，到 2050 年，这一数字将增加到 16.5 亿。到 2020 年，51 岁以上的美国女性将超过 5000 万。预计这种变化在发达国家会更加明显。因此，随着男性和女性年龄的增长，HRT 对老年女性的应用有望扩大，从而导致市场增长。

根据美国妇产科学院的数据，每天约有 6,000 名女性经历更年期。多个品牌和仿製药的存在以及女性意识的提高预计将成为提色增强因素的重大影响。

按产品划分，预计在预测期内雌激素细分市场将占据最大的市场份额。

HRT 市场按产品细分为雌激素、睪酮、人类生长激素和甲状腺激素疗法。其中，雌激素替代疗法部分将在 2021 年占据最大的市场份额，因为基于雌激素的产品已被研究以产生最多的处方。雌激素替代疗法用于绝经后和子宫切除术的妇女，以帮助维持荷尔蒙平衡。

另一方面，人类生长激素疗法预计在预测期内以最快的复合年增长率增长，尤其是由于婴儿生长障碍的发生率不断增加。例如，根据世卫组织赞助的一项研究，约有 1500 万新生儿早产，其中约 85% 未完全发育。激素疗法也用于成人治疗短肠综合征和垂体瘤等疾病。

区域介绍

北美在全球激素替代疗法市场中占有最大的市场份额。

由于美国和加拿大的老年人口不断增加，北美地区将在 2021 年占据全球激素替代疗法市场的最大份额。根据美国国立卫生研究院 (NIH) 的数据，美国近一半的绝经后妇女报告说，她们一生中至少使用过一次激素替代疗法。含有雌激素和选择性雌激素受体调节剂的结合马雌激素 (CEE)/巴多昔芬片剂在美国上市，用于治疗绝经期 VMS 和预防骨质疏鬆症。总体而言，由于女性越来越多地采用激素替代疗法进行绝经后和更年期管理，预计美国激素替代疗法市场在预测期内将出现高速增长。

亚太地区是全球激素替代疗法增长最快的市场

预计亚太地区 HRT 市场将在 2022-2029 年的预测期内出现最快的增长。医疗保健专业人员对对抗激素缺乏症的认识和兴趣的提高预计将推动该地区的市场增长。

竞争格局。

激素替代疗法市场正在巩固和竞争。为市场增长做出贡献的主要参与者包括雅培、辉瑞、拜耳、诺华、艾尔建、诺和诺德、Mylan NV、F. Hoffmann-La Roche、礼来公司等。领先的公司正在采取多种增长战略，例如产品发布、收购和合作伙伴关係，这有助于全球激素替代疗法市场的增长。例如，2019 年 11 月 23 日，Theramex 获得了 Janssen 的 Evorel 贴片的世界版权。此次收购的目的是意识到 HRT 供应链短缺，并专注于解决这一问题。

雅培实验室

概述

Abbott Laboratories 是一家总部位于美国的全球医疗器械和医疗保健公司。它有四个业务部门：医疗设备、诊断、品牌仿製药和营养产品。 2013 年，我们将研究药物业务拆分为 AbbVie。 2020 年 3 月，雅培获得了 FDA 的紧急使用授权（ EUA ），用于 2019 版 nCoV 测试，以帮助缓解 COVID-19大流行。

COVID-19 影响分析

COVID-19 正在通过对生产和需求的直接影响、供应链中断和市场中断以及对企业和金融市场的财务影响来影响全球经济。随着越来越多的利益相关者寻求新的方法来诊断和治疗感染 COVID-19 的患者，全球激素替代疗法 (HRT) 市场受到了 COVID-19 流行病的影响。

外源性雌激素和睪酮疗法具有治疗潜力，可以减轻对 SARS-CoV-2 的有害炎症反应，而不会干扰免疫系统对病毒（如皮质类固醇）的反应。使用阻断炎症标誌物受体的免疫调节剂（例如 anarka [IL-1 受体阻断剂]、托珠单抗和 sarilumab）来减轻对 SARS-CoV-2 的放大和组织损伤性免疫反应。[IL-6 受体拮抗剂] ）。然而，人们担心这些药物可能会对患者的免疫功能产生不利影响。

伦敦国王学院、利物浦大学、佐伊全球有限公司的一项研究将女性的高雌激素水平与低 COVID-19 感染和严重程度联繫起来，旨在帮助评估雌激素治疗潜力 我们检查了性别的存在与否。

结果显示，服用 HRT 的绝经后妇女对 COVID-19 的预测率更高，相关症状的发生频率也更高，但并未住院。 HRT 的使用与较低的呼吸支持和阳性检测趋势相关。年龄组分析显示，55-60 岁年龄组获益最大。

研究人员调查了复合口服避孕药 (COCP) 形式的外源性雌激素对 COVID-19 相关症状和感染的影响，以及绝经后妇女对 COVID-19 的激素替代疗法 (HRT) 的影响。还检查了症状的严重程度。

未来，有必要研究激素替代疗法是否在治疗被诊断患有 COVID-19 的老年人中发挥药物治疗作用。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按产品划分的市场细分
  • 按疾病类型划分的市场细分
  • 按管理途径划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
  • 驱动程序
    • 提高女性对绝经后问题的认识
    • 通过新的递送系统增加药物开发
  • 限制因素
    • 激素替代疗法费用高
  • 商机
  • 影响分析

第5章行业分析

  • 波特五力分析
  • 管道分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品分类

  • 甲状腺激素替代疗法
  • 雌激素替代疗法
  • 雄性激素替代疗法
  • 人类生长激素替代疗法

第 8 章人类生长激素替代疗法

  • 甲状腺功能减退
  • 更年期
  • 男性性腺机能减退
  • 生长激素缺乏症
  • 其他

第 9 章给药途径

  • 口语
  • 肠胃外
  • 透皮给药
  • 其他

第10章分销渠道

  • 医院药房
  • 零售药店和药店
  • 在线药店
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 13 章公司简介

  • 雅培实验室
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Pfizer, Inc.
  • Bayer AG
  • Novartis AG
  • Allergan Plc
  • Novo Nordisk A/S
  • Mylan NV
  • F. Hoffmann-La Roche
  • Eli Lilly and Company
  • Noven Pharmaceuticals, Inc.（List Not Exhaustive）

第14章 DataM

简介目录
Product Code: DMPH2744

Market Overview

Hormone Replacement Therapy (HRT) market was valued at USD 14,553.5 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 5.1% during the forecast period (2022-2029).

Hormone replacement therapy (HRT) is a technique for replacing and replenishing hormones in the human body, which are at inadequate levels than those required for the normal physiology of the human body. Hormone replacement therapy helps to balance the estrogen and progesterone levels during or near menopause. During menopause, hormonal therapy or menopausal hormone therapy, hormone replacement therapy helps to relieve hot flashes, sweating, and other symptoms of menopause. HR therapy has also been proved to prevent bone loss and reduce fracture in postmenopausal women. Systemic hormone therapy which comes in pill, cream, spray form, skin patch, or gel is one of the most effective treatments for the relief of menopausal hot flashes and night sweats.

Market Dynamics

The hormone replacement therapy market growth is driven by some of the major factors such as growing awareness of post-menopausal issues among women, increasing drug development with novel delivery systems, and hormonal imbalance disorders with the growing geriatric population.

Rising hormonal imbalance disorders with a growing geriatric population drive the HRT market growth

Hormonal imbalance disorders, with a growing geriatric population, is one of the major factors driving the growth of the HRT market. With several hormonal changes, the female body predominantly gets affected by the natural process of aging, which leads to abnormalities and diseases. Some of the common problems include fatigue, weight gain, memory decline, low libido, aging appearance, and muscle loss.

The most frequent consequence of age-related hormonal changes occurs in cases related to menopause. The global average onset age for menopause among women is approximately 50 years. In women, the production levels of estrogen and progesterone decrease significantly by the age of 50 years and above. This decrease in production levels of estrogen and progesterone is compensated by the pituitary gland, with the increased production of follicle-stimulating hormone (FSH). This is physically manifested in women in the form of post-menopause symptoms, which include flush.

Increasing Development in the Hormone Replacement Therapy

The hormone replacement therapy market has observed significant development over the past few years and is expected to grow significantly during the forecast period. With the increasing frequencies of hormonal lopsidedness issues and expanding age and the neonatal populace, these sicknesses are foreseen to advance development. The rising interest in hormone replacement therapy is driven by the existence of routinely observed details, growing technological progression in the field of drug delivery frameworks, and rising awareness among patients. Menopausal females frame the biggest segment influencing the market and subsequently, the rising female populace between the age gathering of 45 to 59 and expanding the scope of the menopausal window are anticipated to push development.

In January 2020, a new menopause health service has launched in California that offers women remote consultations and, for the first time, mail-order prescriptions of menopause hormone replacement therapies. The telemedicine platform, called CurieMD, offers consumers video consultation with a board-certified midlife health practitioner (free at launch, and $39 for follow-up appointments). The FDA-approved bio-identical hormone treatments on offer come as oral tablets, vaginal creams, and oral contraceptive pills, and are offered as quarterly payment plans.

Side effects and risks associated with HRT might hamper the market growth

Hormone Replacement Therapy has several side effects such as indigestion, depression, fluid retention, headache, among others. These side effects are anticipated to hamper the adoption of this therapy.

Hormone replacement therapy might cause some risks for people with uncontrolled hypertension, or high blood pressure, thrombosis or blood clots, high levels of triglycerides in the blood, stroke, heart disease, breast cancer, and gallbladder disease.

Also, according to a UK-based NICE finding, hormone replacement therapy is associated with breast cancer risk if the drugs progesterone and oestrogen are taken in combination. Prolonged consumption of HRT drugs might lead to an increased risk of blood clots also. Every 1,000 women taking HRT tablets for 7.5 years, less than two will develop a blood clot, as per some studies.

Epidemiology

Hypothyroidism:

According to the National Health and Nutrition Examination Survey (NHANES 1999-2002), of 4392 individuals reflecting the US population reported hypothyroidism (defined as TSH levels exceeding 4.5 mIU/L) in 3.7% of the population. Hypothyroidism is most common in women with small body size at birth and low body mass index during childhood.

Iodine deficiency as a cause of hypothyroidism is more common in less-developed countries. Routine supplementation of salt, flour, and other food staples with iodine has decreased the rates of iodine deficiency.

The World Health Organization (WHO) data from 130 countries taken from January 1994 through December 2006 found inadequate iodine nutrition in 30.6% of the population. The WHO recommends urinary iodine concentrations between 100 and 199 μg/L in the general population and a range of 150-249 μg/L in pregnant women.

The frequency of hypothyroidism, goiters, and thyroid nodules increases with age. Hypothyroidism is most prevalent in elderly populations, with 2-20% of older age groups having some form of hypothyroidism. The Framingham study found hypothyroidism (TSH > 10 mIU/L) in 5.9% of women and 2.4% of men older than 60 years. In NHANES 1999-2002, the odds of having hypothyroidism were five times greater in persons aged 80 years and older than in individuals aged 12-49 years.

The NHANES 1999-2002 reported that the prevalence of hypothyroidism was higher in whites (5.1%) and Mexican Americans than in African Americans (1.7%). The African Americans tend to have lower median TSH values.

Market Segmentation

The global hormone replacement therapy (HRT) market is segmented based on the product, disease type, route of administration, and distribution channel.

Based on Disease, Menopause is Expected to Growth at High CAGR over the Forecast Period

Menopause is the stage that marks the end of the menstrual cycle. It is diagnosed after 12 months without a menstrual period. Menopause can happen at the age of 40 or 50. Menopause is a natural biological process. Hormone replacement therapy improves the quality of life and prolongs life for elderly women, whether it is initiated at menopause or much later. The therapy helps elderly women maintain their estrogen levels.

The menopause segment growth is expected to increase as the geriatric population globally increases. The United Nations has estimated that 980 million women globally in 2020 are aged 50 and over. This figure can be further estimated to rise to 1.65 billion by 2050. In 2020, the number of United States women aged older than 51 years was expected to be more than 50 million. This change is expected to be more prevalent in developed countries. Hence, as both men and women age, the application of HRT in older women is expected to grow, which will help the market growth.

As per the American Congress of Obstetricians and Gynecologists, about 6,000 women reach menopause daily. The presence of several branded and generic drugs and growing awareness among women are expected to be the vital impact of rendering drivers.

By Product, Estrogen Segment is Expected to Hold Largest Market Share During the Forecast Period

Based on product, the HRT market is segmented into therapies for estrogen, testosterone, human growth hormone, and thyroid hormones. Among these, the estrogen hormone replacement therapy segment accounted for the largest market share in 2021, as estrogen-based products have been studied to generate the largest number of prescriptions. Estrogen replacement therapy is used in women during post-menopause or hysterectomy, which helps them to maintain the hormonal balance.

On the other hand, the human growth hormone therapy is expected to grow at the fastest CAGR over the forecast period due to the increasing incidences of growth deficiencies, especially in infants. For instance, as per a survey organized by the WHO, around 15 million newborns are born premature, and around 85% of these infants are not fully developed. In adults, hormone therapy is provided for conditions such as short bowel syndrome and pituitary tumors.

Geographical Presentation

North America region holds the largest market share in the global Hormone Replacement Therapy market

North America region is dominating the global hormone replacement therapy market accounted for the largest market share in 2021, owing to the growing geriatric population in the United States and Canada. As per the National Institutes of Health (NIH), almost half of all the post-menopausal women in the United States reported having used hormone replacement therapy at least once in their life. The conjugated equine estrogens (CEE)/bazedoxifene tablet, a combination of estrogen and a selective estrogen receptor modulator, is available in the U.S. for menopausal VMS treatment and osteoporosis prevention. Overall, the market for hormone replacement therapy in the United States is scheduled for high growth over the forecast period, due to the growing adoption of hormone replacement therapy among women, for both post-menopausal and menopause management.

The Asia Pacific is the fastest-growing market in the global hormone replacement therapy market

The Asia Pacific HRT market is expected to witness the fastest growth over the forecast period from 2022 to 2029. Increasing awareness levels and the rising focus of healthcare providers on the eradication of hormonal deficiencies are expected to boost the growth of the market within the region.

Competitive Landscape:

The hormone replacement therapy market is consolidated and competitive. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Pfizer, Inc., Bayer AG, Novartis AG, Allergan Plc, Novo Nordisk A/S, Mylan NV, F. Hoffmann-La Roche, Eli Lilly, and Company, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the hormone replacement therapy market globally. For instance, on 23rd November 2019, Theramex acquired global rights to Janssen's Evorel patches. This acquisition aims needs to be aware of the supply chain of HRT shortages and is dedicated to resolving this issue.

Abbott Laboratories

Overview:

Abbott Laboratories headquarters in the United States is a global medical device and health care company. The company has four business segments: medical devices, diagnostics, branded generic medicines, and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013. In March 2020, Abbott received emergency use authorization (EUA) from the FDA for a 2019-nCoV test to help mitigate the COVID-19 pandemic.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global hormone replacement therapy (HRT) market has been impacted by the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.

Exogenous estrogen and testosterone therapies have a therapeutic potential to mitigate the damaging inflammatory response to SARS-CoV-2 without hampering the immune system's response to the virus as corticosteroids do. The use of immune-modulating drugs to block inflammatory markers' receptors to mitigate the amplified and tissue-damaging immune response of SARS-CoV-2 (eg, anarka [an IL-1 receptor blocker] and tocilizumab and sarilumab [IL-6 receptor antagonists]). However, there are concerns about these agents' possible adverse effects on the patient's immune function.

According to research from King's College London, the University of Liverpool, and Zoe Global Limited, aimed at contributing to an evaluation of the potential for estrogen treatment in COVID-19, by examining the presence of an association between high estrogen levels and lower levels of COVID-19 infection and severity in women.

The researchers showed that the rate of predicted COVID-19 was higher in postmenopausal women on HRT, who also showed a higher frequency of related symptoms but not of hospitalization. HRT use was associated with a trend towards lower respiratory support and positive testing. The age-group analysis showed the effects to be highest in the 55-60-year age group.

The researchers also looked at the effect of exogenous estrogen in the form of the combined oral contraceptive pill (COCP) on COVID-19-related symptoms and infection, and the effect of hormone replacement therapy (HRT) on COVID-19 positivity and symptom severity in women past menopause.

There is a need for future research to examine whether hormone replacement therapy may have a pharmacotherapeutic role in treating older adults diagnosed with COVID-19.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Disease Type
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Growing Awareness on Post-menopausal Issues among Women
    • 4.2.2. Increasing Drug Development with Novel Delivery Systems
    • 4.2.3. XX
  • 4.3. Restraints
    • 4.3.1. High Cost of Hormone Replacement Therapy
    • 4.3.2. XX
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
    • 7.1.2. Market Attractiveness Index, By Product Segment
  • 7.2. Thyroid Hormone Replacement Therapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Estrogen Hormone Replacement Therapy
  • 7.4. Testosterone Hormone Replacement Therapy
  • 7.5. Human Growth Hormone Replacement Therapy

8. Human Growth Hormone Replacement Therapy

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
    • 8.1.2. Market Attractiveness Index, By Disease Type Segment
  • 8.2. Hypothyroidism*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Menopause
  • 8.4. Male Hypogonadism
  • 8.5. Growth Hormone Deficiency
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Transdermal
  • 9.5. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies and Drugstores
  • 10.4. Online Pharmacy
  • 10.5. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Pfizer, Inc.
  • 13.3. Bayer AG
  • 13.4. Novartis AG
  • 13.5. Allergan Plc
  • 13.6. Novo Nordisk A/S
  • 13.7. Mylan NV
  • 13.8. F. Hoffmann-La Roche
  • 13.9. Eli Lilly and Company
  • 13.10. Noven Pharmaceuticals, Inc. (List Not Exhaustive)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us